Biogen
- Country
- 🇺🇸United States
- Ownership
- Private
- Established
- 1978-01-01
- Employees
- 7.5K
- Market Cap
- $29.6B
- Website
- https://www.biogen.com
- Introduction
Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. Its products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS, SPINRAZA for the treatment of SMA, ADUHELM for the treatment of Alzheimer's disease, and FUMADERM for the treatment of severe plaque psoriasis. The company was founded by Charles Weissmann, Heinz Schaller, Kenneth Murray, Walter Gilbert, and Phillip Allen Sharp in 1978 and is headquartered in Cambridge, MA.
TYSABRI Global Observational Program in Safety
- Conditions
- Multiple Sclerosis
- First Posted Date
- 2007-05-22
- Last Posted Date
- 2015-06-22
- Lead Sponsor
- Biogen
- Target Recruit Count
- 2207
- Registration Number
- NCT00477113
- Locations
- 🇺🇸
There may be mulitple sites in this clinical trial. Contact United BioSource Corporation, Kansas City, Missouri, United States
Pregnancy Exposure Registry for Tysabri®
- Conditions
- Multiple SclerosisCrohn's DiseasePregnancyPrenatal Exposure
- First Posted Date
- 2007-05-14
- Last Posted Date
- 2014-08-11
- Lead Sponsor
- Biogen
- Target Recruit Count
- 376
- Registration Number
- NCT00472992
- Locations
- 🇺🇸
United BioSource Corporation, Morgantown, West Virginia, United States
Evaluation of Natalizumab for thE Relief of MS Associated FatiGue
- Conditions
- Multiple Sclerosis
- First Posted Date
- 2007-04-20
- Last Posted Date
- 2023-08-22
- Lead Sponsor
- Biogen
- Target Recruit Count
- 89
- Registration Number
- NCT00464074
- Locations
- 🇵🇷
Research Site, Guaynabo, Puerto Rico
BG9924 in Combination With Methotrexate for Participants With Active Rheumatoid Arthritis
- Conditions
- Rheumatoid Arthritis
- Interventions
- Other: Placebo ComparatorBiological: BG9924
- First Posted Date
- 2007-04-11
- Last Posted Date
- 2016-01-21
- Lead Sponsor
- Biogen
- Target Recruit Count
- 115
- Registration Number
- NCT00458861
- Locations
- 🇺🇸
Stanford University, Palo Alto, California, United States
BIIB014 Phase 2a Monotherapy
- Conditions
- Parkinson's Disease
- First Posted Date
- 2007-03-26
- Last Posted Date
- 2023-08-23
- Lead Sponsor
- Biogen
- Registration Number
- NCT00451815
Efficacy and Safety Study of Oral BG00012 With Active Reference in Relapsing-Remitting Multiple Sclerosis
- Conditions
- Relapsing-Remitting Multiple Sclerosis
- Interventions
- First Posted Date
- 2007-03-23
- Last Posted Date
- 2015-01-26
- Lead Sponsor
- Biogen
- Target Recruit Count
- 1417
- Registration Number
- NCT00451451
- Locations
- 🇺🇦
Research Site, Zaporozhye, Ukraine
Dose-Finding Safety Study of BIIB014 in Early-Stage Parkinson's Disease
- First Posted Date
- 2007-03-02
- Last Posted Date
- 2009-01-09
- Lead Sponsor
- Biogen
- Target Recruit Count
- 36
- Registration Number
- NCT00442780
- Locations
- 🇷🇸
Research Sites, Belgrade, Serbia
🇷🇸Research Site, Belgrade, Serbia
Dose-Finding Safety Study of BIIB014 in Combination With Levodopa in Moderate to Late Stage Parkinson's Disease
- First Posted Date
- 2007-02-22
- Last Posted Date
- 2009-07-13
- Lead Sponsor
- Biogen
- Target Recruit Count
- 83
- Registration Number
- NCT00438607
- Locations
- 🇮🇳
Research Sites, Bangalore, India
🇬🇧Research Site, Salford, United Kingdom
A Multicenter Study to Assess the Effect of Plasma Exchange in Accelerating the Clearance of Natalizumab in Subjects With Multiple Sclerosis (MS)
- Conditions
- Relapsing Forms of Multiple Sclerosis
- First Posted Date
- 2007-01-22
- Last Posted Date
- 2009-09-04
- Lead Sponsor
- Biogen
- Target Recruit Count
- 12
- Registration Number
- NCT00424788
- Locations
- 🇺🇸
Cleveland Clinic Mellen Center for MS, Cleveland, Ohio, United States
🇺🇸Center for Neurological Disorders, Aurora Health Care, Milwaukee, Wisconsin, United States
Efficacy and Safety of Oral BG00012 in Relapsing-Remitting Multiple Sclerosis
- Conditions
- Relapsing-Remitting Multiple Sclerosis
- Interventions
- Drug: Placebo
- First Posted Date
- 2007-01-11
- Last Posted Date
- 2015-01-26
- Lead Sponsor
- Biogen
- Target Recruit Count
- 1234
- Registration Number
- NCT00420212
- Locations
- 🇻🇮
Research Site, Vienna, Virgin Islands (U.S.)